Human Papillomavirus (HPV) Screening in vaccinated populations: a clinical and cost-effectiveness model

Descriptions

The contract is for the provision of a clinical and cost-effectiveness model for Human Papillomavirus (HPV) Screening in vaccinated populations. This model will project and compare the health benefits, harms, and costs associated with a range of strategies for HPV screening in vaccinated populations.Contract Value: £280,000 excluding VAT; £336,000 including VATContract Term: From 05/05/2022 to 31/12/2023, with the option to extend for 6 months at the sole discretion of the contracting authority and for the purpose of completing the contract outcomes.The opportunity will be available on the DHSC Atamis eTendering System. Select this link to access and register your organisation to the Atamis system https://health-family.force.com/s/Welcome, if you have not already done so.To find this opportunity in the eTendering system, select “Find Opportunities” and then search by project number or title. Once you have found the Opportunity, press the ‘Register Interest’ button to register your interest. This will make the project to appear on ‘My proposals and quotes’. From there you can review documents, send clarification messages, submit the response, or decline to respond, if you decide not to participate in the opportunity.For full details on the instruction to tender and terms of participations please refer to the Invitation to Tender document.